Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J

Executive Summary

Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.

You may also be interested in...



In Brief: GSK, Bristol/Pfizer See Approvals, Baxter Holds Its Own in Hemophilia

Recent Phase III releases include data for Actavis’ ceftazidime/avibactam for gram-negative abdominal infections and Baxter’s long-acting Factor VIII hemophilia drug BAX 855. GSK’s fluticasone approved for asthma and Bristol/Pfizer’s Eliquis expands labeling.

Deal Watch: Allergan Makes Another Defensive Play Against Valeant Takeover

In a pair of diabetes-related transaction, Sanofi pays $175 million upfront to MannKind for worldwide license to inhaled insulin Afrezza, while Janssen options Phase I stem cell program from ViaCyte. Novartis gets purchase option for stem-cell biotech Gamida Cell and MorphoSys in-licenses a preclinical prostate cancer antibody candidate from Emergent BioSolutions.

FDA Draws Regulatory Line Between Moxduo, HIV Combos

HIV products often increase potency in combination, agency says.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS056185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel